Next Article in Journal
Targeting Common Inflammatory Mediators in Experimental Severe Asthma and Acute Lung Injury
Next Article in Special Issue
AutoPepVax, a Novel Machine-Learning-Based Program for Vaccine Design: Application to a Pan-Cancer Vaccine Targeting EGFR Missense Mutations
Previous Article in Journal
Differentiation of Pluripotent Stem Cells for Disease Modeling: Learning from Heart Development
Previous Article in Special Issue
Heterocycles 52: The Drug-Likeness Analysis of Anti-Inflammatory Thiazolo[3,2-b][1,2,4]triazole and Imidazo[2,1-b][1,3,4]thiadiazole Derivatives
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Identification of mIDH1 R132C/S280F Inhibitors from Natural Products by Integrated Molecular Docking, Pharmacophore Modeling and Molecular Dynamics Simulations

1
College of Pharmacy, Shaanxi University of Chinese Medicine, Shiji Ave., Xi’an-Xianyang New Ecomic Zone, Xianyang712046, China
2
Dr. Neher’s Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macao 999078, China
3
Guangzhou Laboratory, Guangzhou 510005, China
*
Author to whom correspondence should be addressed.
Pharmaceuticals 2024, 17(3), 336; https://doi.org/10.3390/ph17030336
Submission received: 5 February 2024 / Revised: 26 February 2024 / Accepted: 29 February 2024 / Published: 5 March 2024
(This article belongs to the Special Issue Computer-Aided Drug Design and Drug Discovery)

Abstract

Mutant isocitrate dehydrogenase 1 (mIDH1) is a common driving factor in acute myeloid leukemia (AML), with the R132 mutation accounting for a high proportion. The U.S. Food and Drug Administration (FDA) approved Ivosidenib, a molecular entity that targets IDH1 with R132 mutations, as a promising therapeutic option for AML with mIDH1 in 2018. It was of concern that the occurrence of disease resistance or recurrence, attributed to the IDH1 R132C/S280F second site mutation, was observed in certain patients treated with Ivosidenib within the same year. Furthermore, it should be noted that most mIDH1 inhibitors demonstrated limited efficacy against mutations at this specific site. Therefore, there is an urgent need to investigate novel inhibitors targeting mIDH1 for combating resistance caused by IDH1 R132C/S280F mutations in AML. This study aimed to identify novel mIDH1 R132C/S280F inhibitors through an integrated strategy of combining virtual screening and dynamics simulations. First, 2000 hits were obtained through structure-based virtual screening of the COCONUT database, and hits with better scores than −10.67 kcal/mol were obtained through molecular docking. A total of 12 potential small molecule inhibitors were identified through pharmacophore modeling screening and Prime MM-GBSA. Dynamics simulations were used to study the binding modes between the positive drug and the first three hits and IDH1 carrying the R132C/S280F mutation. RMSD showed that the four dynamics simulation systems remained stable, and RMSF and Rg showed that the screened molecules have similar local flexibility and tightness to the positive drug. Finally, the lowest energy conformation, hydrogen bond analysis, and free energy decomposition results indicate that in the entire system the key residues LEU120, TRP124, TRP267, and VAL281 mainly contribute van der Waals forces to the interaction, while the key residues VAL276 and CYS379 mainly contribute electrostatic forces.
Keywords: IDH1 R132C/S280F mutations; molecular docking; pharmacophore modeling; ADMET; molecular dynamics simulations IDH1 R132C/S280F mutations; molecular docking; pharmacophore modeling; ADMET; molecular dynamics simulations
Graphical Abstract

Share and Cite

MDPI and ACS Style

Zhang, W.; Bai, H.; Wang, Y.; Wang, X.; Jin, R.; Guo, H.; Lai, H.; Tang, Y.; Wang, Y. Identification of mIDH1 R132C/S280F Inhibitors from Natural Products by Integrated Molecular Docking, Pharmacophore Modeling and Molecular Dynamics Simulations. Pharmaceuticals 2024, 17, 336. https://doi.org/10.3390/ph17030336

AMA Style

Zhang W, Bai H, Wang Y, Wang X, Jin R, Guo H, Lai H, Tang Y, Wang Y. Identification of mIDH1 R132C/S280F Inhibitors from Natural Products by Integrated Molecular Docking, Pharmacophore Modeling and Molecular Dynamics Simulations. Pharmaceuticals. 2024; 17(3):336. https://doi.org/10.3390/ph17030336

Chicago/Turabian Style

Zhang, Weitong, Hailong Bai, Yifan Wang, Xiaorui Wang, Ruyi Jin, Hui Guo, Huanling Lai, Yuping Tang, and Yuwei Wang. 2024. "Identification of mIDH1 R132C/S280F Inhibitors from Natural Products by Integrated Molecular Docking, Pharmacophore Modeling and Molecular Dynamics Simulations" Pharmaceuticals 17, no. 3: 336. https://doi.org/10.3390/ph17030336

APA Style

Zhang, W., Bai, H., Wang, Y., Wang, X., Jin, R., Guo, H., Lai, H., Tang, Y., & Wang, Y. (2024). Identification of mIDH1 R132C/S280F Inhibitors from Natural Products by Integrated Molecular Docking, Pharmacophore Modeling and Molecular Dynamics Simulations. Pharmaceuticals, 17(3), 336. https://doi.org/10.3390/ph17030336

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop